Mentari Therapeutics, Inc. filed a Form 8-K on November 16, 2026, submitting unaudited condensed consolidated financial statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2026, following its merger closing on November 6, 2026.

Key Highlights

  • Merger closed November 6, 2026: The company disclosed that the business combination between InMed Pharmaceuticals Inc. and private Delaware corporation Mentari Therapeutics, Inc. was consummated on that date.
  • Name change completed: InMed Pharmaceuticals Inc., formerly a British Columbia corporation, became Mentari Therapeutics, Inc., a Nevada corporation, upon closing.
  • Financial statements filed: Unaudited condensed consolidated financial statements of Mentari as of September 30, 2026, and for the three and nine months ended September 30, 2026, were attached as Exhibit 99.1.
  • MD&A included: Management's Discussion and Analysis for the three and nine months ended September 30, 2026, was attached as Exhibit 99.2.
  • S-4 registration effective October 1, 2026: The definitive proxy statement/prospectus (File No. 333-297234) was most recently amended September 29, 2026, and declared effective October 1, 2026.
  • Item 2.02 furnished, not filed: The results of operations disclosure "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," according to the filing.

Post-Merger Financial Disclosures for Mentari Therapeutics After InMed Combination

According to the filing, Mentari Therapeutics, Inc. (NASDAQ:MTRI) submitted this Current Report on Form 8-K to provide financial information relating to the recently completed merger. The business combination was carried out pursuant to an Agreement and Plan of Merger and Reorganization dated May 19, 2026, as amended, involving InMed, two merger subsidiaries (Indigo Merger Sub Corp., a Delaware corporation, and Indigo Merger Sub II, LLC, a Delaware limited liability company), and the private Delaware corporation formerly known as Mentari Therapeutics, Inc.

The company disclosed that the unaudited condensed consolidated financial statements filed as Exhibit 99.1 cover the period as of September 30, 2026, and for the three and nine months ended on that date. These statements are accompanied by related notes. The filing states that Exhibit 99.2 contains Mentari's Management's Discussion and Analysis of Financial Condition and Results of Operations for the same periods. Both exhibits are incorporated by reference into Item 2.01 and Item 2.02 of the report. The signing officer is Jerad G. Seurer, identified as General Counsel and Corporate Secretary.

Regarding risk factors, the filing directs readers to the Proxy Statement/Prospectus filed on Form S-4 (File No. 333-297234), which describes risks related to Mentari's business beginning on page 84, risks related to the Redomestication beginning on page 122, and risks related to the combined company beginning on page 124. The filing does not reproduce the financial figures from the exhibits within the body of the 8-K itself; those disclosures are contained in the attached exhibits.

What Was Disclosed

Mentari Therapeutics filed an 8-K on November 16, 2026, to submit unaudited financial statements and MD&A for the period ended September 30, 2026, in connection with the November 6, 2026 merger closing that transformed InMed Pharmaceuticals into Mentari Therapeutics, a Nevada corporation listed on the Nasdaq Capital Market.